Insulet (PODD) The Baird 2024 Global Healthcare Conference summary

Strategic market positioning and product innovation

• Omnipod 5 is a wearable, disposable, tubeless insulin delivery device, now the most prescribed and patient-preferred automated insulin delivery system in the U.S. and a top choice for first-time users in Europe in 2023.

• The platform integrates with leading continuous glucose monitors, is cloud-connected, and can be controlled via smartphone, supporting superior clinical outcomes and quality of life.

• Omnipod 5 is available in 25 countries, targeting both mature and under-penetrated markets, with a focus on expanding access to those not yet using technology.

• Recent FDA clearance allows Omnipod 5 to serve U.S. patients with insulin-requiring Type 2 diabetes, opening a large, under-penetrated segment.

• New manufacturing capacity in Malaysia and upcoming iOS app and sensor integrations are set to further support growth.

Growth, financial performance, and guidance

• Revenue has grown at a 22% CAGR over five years, with 2023 guidance at $2 billion, gross margin at 69%, and operating income at 14%, reflecting significant margin expansion.

• Q2 results led to increased guidance across the P&L, with sequential growth in new U.S. customer starts expected in the second half of 2024.

• International growth guidance was raised from 7%-10% to 18%-21% constant currency, driven by rapid adoption in the U.K., Germany, France, and the Netherlands.

• Margin expansion is expected to continue in 2025, supported by scale, gradual sales force expansion, and top-line growth.

• Management targets at least 100 basis points of margin expansion annually, balancing reinvestment for growth with profitability.

Type 2 diabetes market opportunity and adoption strategy

• U.S. Type 2 insulin pump market is under 5% penetrated; SECURE-T2D study showed up to 2-point A1C reduction, supporting strong clinical value.

• On-label approval enables direct engagement with healthcare providers and patients, with targeted sales and DTC efforts beginning immediately.

• Initial focus is on patients with A1C >8, already using CGM, and not achieving desired outcomes; adoption expected to build office by office over several quarters.

• Sales force expansion to high-prescribing non-endocrinologists will begin in Q4 2024 to drive 2025 growth.

• Management expects Type 2 to be additive to growth, with penetration and revenue contribution accelerating over the next few years.